Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
|Webcasts|July 14, 2022
Accurate Determination of Mutagenic Azido, NDSRI, and Nitrosamine Impurities in Drug Substances and Products Using LC–MS/MS
Author(s)Agilent
Thursday, July 14th, 2022 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST Join us to learn approaches for the accurate determination of mutagenic azido, NDSRI, and nitrosamine impurities in drug substances and products using LC–MS/MS.
Register Free:
Event Abstract:
Several sartan, ranitidine, and metformin-based drug products have been recalled due to nitrosamine contamination, in unacceptable amounts, in these drugs. Since then, there has been increased scrutiny by the regulators to accurately identify and quantify mutagenic impurities in drug substances and products. The US FDA and other regulatory agencies have published analytical testing guidance documents regarding the evaluation of mutagenic nitrosamine impurities in these drug substances and drug products. Recently, sartan therapeutics were again recalled due to another known mutagenic impurity called azido biphenyl tetrazole (AZBT) impurity. Additionally, there have been recalls related to nitroso impurity in varenicline drug products.
This presentation will address the accurate determination of mutagenic azido impurities, nitroso drug substance related impurities (NDSRIs) and nitrosamine impurities in drug substances and products using liquid chromagraphy–tandem mass spectrometry (LC–MS/MS) based analytical strategies that you can adopt to meet your nitrosamine detection and quantitation needs.
Key Learning Objectives:
- Understand what mutagenic impurities are and the importance of characterizing and quantifying them
- Learn about approaches for the confident identification and quantification of nitroso drug substance related impurities (NDSRIs) and nitrosamine impurities in APIs and drugs
- Learn about approaches for the confident identification and quantification of azido impurities in five different sartan therapeutics
Who Should Attend:
- Laboratory managers
- Chromatographers
- Analytical chemists and scientists
- New product developers
- Pharma quality control manager
Speakers
Kartheek Srinivas Chidella
Application Engineer
Agilent Technologies
Kartheek Srinivas Chidella has more than 13 years of experience in the pharmaceutical and analytical industry working on LC–MS/MS. After completing his M.Sc. (Organic Chemistry) at Andhra University, Kartheek started his career at Dr. Reddys Laboratories in Analytical & Bioanalytical department and developed several LC–MS/MS methods for determination in drugs in biological matrices. He later joined Mylan Laboratories in analytical development and worked on impurity profiling applications using LC–MS/MS. He later joined Waters as an LC–MS technical and application support specialist and now in his current role as application engineer in Agilent, he is actively involved in providing application support for genotoxic impurity applications using LC–MS/MS.
Register Free:
Related to this article
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Trending on Pharmaceutical Technology
1
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
2
Manufacturing Intelligence: Organoids, Organ-on-a-Chip, and the Trust Gap
3
CPHI Milan: Packaging and Delivery Decisions Must Reflect Real-World Care
4
PharmTech AI Pulse Check: On-Prem vs. Cloud AI
5